On Air Now

Listen

Listen Live Now » 101.1 FM Green Bay, WI

Weather

Current Conditions(Green Bay,WI 54303)

More Weather »
65° Feels Like: 65°
Wind: WSW 13 mph Past 24 hrs - Precip: 0”
Current Radar for Zip

Tonight

Scattered Thunderstorms 62°

Tomorrow

Scattered Thunderstorms 78°

Sun Night

Thunderstorms 54°

Alerts

Pfizer kidney cancer drug fails as initial treatment

The entrance of Pfizer World headquaters in New York City, August 31, 2003. REUTERS/Jeff Christensen
The entrance of Pfizer World headquaters in New York City, August 31, 2003. REUTERS/Jeff Christensen

(Reuters) - Pfizer Inc said its kidney cancer drug did not meet the main goal of showing a statistically significant improvement in survival in a late-stage trial without the cancer getting worse.

The trial was testing the drug Inlyta in patients who have received no prior treatments and compared its effects with another kidney cancer drug, sorafenib. Inlyta is already approved to treat kidney cancer that has not responded to prior therapy.

Sorafenib is marketed as Nexavar by Onyx Pharmaceuticals Inc and Germany's Bayer AG. (Reporting by Esha Dey in Bangalore; Editing by Sreejiraj Eluvangal)

Comments